TheraSphere
BOSTON SCIENTIFIC CORPORATION · Decision date Mar 17, 2021
What did the FDA approve?
The FDA approved TheraSphere, a microspheres radionuclide device from Boston Scientific Corporation, on March 17, 2021. The approval covers selective internal radiation therapy for local tumor control of solitary tumors 1–8 cm in diameter in patients with unresectable hepatocellular carcinoma, Child-Pugh Score A cirrhosis, well-compensated liver function, no macrovascular invasion, and good performance status.
The record does not identify a supplement type or reason, so this appears as an original PMA approval rather than a change to a prior system. The statement reports the device's indicated use; it does not independently establish safety or clinical effectiveness beyond that regulatory description.
FDA approval order statement
Approval for TheraSphereTM. This device is indicated for use as selective internal radiation therapy (SIRT) for local tumor control of solitary tumors (1-8 cm in diameter), in patients with unresectable hepatocellular carcinoma (HCC), Child-Pugh Score A cirrhosis, well-compensated liver function, no macrovascular invasion, and good performance status.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Radiology
- Decision date
- Mar 17, 2021
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P200029
- Regulatory pathway
- Premarket approval application
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- NAW
- Decision code
- APPR
- Decision date
- Mar 17, 2021
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Microspheres radionuclide.
- Applicant
- Boston Scientific Corporation
- Product code
- NAW
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P200029 received
Application receipt date recorded by FDA.
P200029 · FDA decision
APPR
P200029/S015 · Related supplement
TheraSphere Y-90 Glass Microspheres System
Timeline entries are records held by MedtechLedger for P200029. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200029
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TheraSphere Y-90 Glass Microspheres SystemP200029/S015 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Oct 13, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 300 Boston Scientific Way, Marborough, MA, 01752
Sources and methodology
- Original FDA record: P200029
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records